A 17-year-old-mother seeking contraception

JAMA

Volumn 276, Issue 14, 1996, Pages 1163-1170

  Grimes, David A ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Aiza Pharmaceuticals   (United States)

^c Gynopharma Inc   (United States)

^d Mead Johnson Nutritionals   (United States)

^e Ortho McNeil Pharmaceutical Incorporated   (United States)

^f Schmid Products Co   (United States)

^g PFIZER INC   (United States)

^h BAYER PHARMA AG   (Germany)

ⁱ WYETH AYERST RESEARCH   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHOLESTEROL; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADOLESCENT PREGNANCY; ARTICLE; CASE REPORT; CHLAMYDIASIS; CONDOM; CONTRACEPTION; FEMALE; HAIR LOSS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PRIORITY JOURNAL; VAGINA BLEEDING;

EID: 0029762814     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.14.1163     Document Type: Article

References (49)

1. Alan Guttmacher Institute. Sex and America's Teenagers. New York, NY: Alan Guttmacher Institute; 1994.
2. Jones EF, Forrest JD, Goldman N, et al. Teenage pregnancy in developed countries: determinants and policy implications. Fam Plann Perspect. 1985; 17:53-63.
3. Brown SS, Eisenberg L, eds. The Best Intentions: Unintended Pregnancy and the Well-being of Children and Families. Washington, DC: National Academy Press; 1995.
4. Moore KA, Nord CW, Peterson JL. Nonvoluntary sexual activity among adolescents. Fam Plann Perspect. 1989;21:110-114.
5. Zabin LS, Kantner JF, Zelnik M. The risk of adolescent pregnancy in the first months of intercourse. Fam Plann Perspect. 1979;11:215-222.
6. Forrest JD, Gold RB, Kenney AM. The Need, Availability and Financing of Reproductive Health Services. New York, NY: Alan Guttmacher Institute; 1989:36.
7. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health. 1995;85:494-503.
8. Forrest JD, Singh S. The sexual and reproductive behavior of American women, 1982-1988. Fam Plann Perspect. 1990;22:206-214.
9. Jones EF, Forrest JD. Contraceptive failure rates based on the 1988 NSFG. Fam Plann Perspect. 1992;24:12-19.
10. Trussell J, Hatcher RA, Cates W Jr, Stewart FH, Kost K. Contraceptive failure in the United States: an update. Stud Fam Plann. 1990;21:51-54.
11. Droegemueller W, Katta LR, Bright TG, Bowes WA Jr. Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989;161:1407-1411.
12. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1995.
13. Saleh WA, Burkman RT, Zacur HA, Kimball AW, Kwiterovich P, Bell WK. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol. 1993; 168:1740-1747.
14. Woods EF, Grace F, Havens KK, Merola JL, Emans SJ. Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. Am J Obstet Gynecol. 1992;166:901-907.
15. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. 1995;51:149-153.
16. Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health. 1995;16:379-384.
17. Smith RD, Cromer BA, Hayes JR, et al. Medroxyprogesterone acetate (Depo-Provera) use in adolescents: uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates. Adolesc Pediatr Gynecol. 1995;8:24-28.
18. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril. 1995;63:516-521.
19. Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol. 1994;170:1543-1549.
20. Arroyo P, Avila-Rosas H, Fernandez V, Casanueva E, Galvan D. Parity and the prevalence of overweight Int J Gynaecol Obstet. 1995;48:269-272.
21. Rossner S, Ohlin A. Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Obes Res. 1995;3(suppl 2):267s-275s.
22. Srinivasan SR, Bao W, Wattingney WA, Berenson GS. Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study. Metabolism. 1996;45:235-240.
23. Cormia FE. Alopecia from oral contraceptives. JAMA. 1967;201:141-143.
24. Kato K, Joachim A, Nielsen P, Habib ND. Norplant and its side effects. Zentralbl Gynakol. 1995;117:260-262.
25. Marx PA, Gerde A, Dailey P, et al. Systemic progesterone enhances SIV vaginal transmission and promotes disease progression. Presented at the American Society for Clinical Investigation; May 6, 1996; Washington, DC.
26. McGregor JA, Hammill HA. Contraception and sexually transmitted diseases: interactions and opportunities. Am J Obstet Gynecol. 1993;168:2033-2041.
27. Gray RH. Reduced risk of pelvic inflammatory disease with injectable contraceptives. Lancet. 1985;1:1046.
28. Ho PC, Kwan MSW. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod. 1993;8:389-392.
29. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13-16.
30. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994; 308:247-248.
31. Naessen T, Olsson S-E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraceptoin. 1995;52:35-39.
32. Virutamasen P, Wangsuphachart S, Reinprayoon D, Kriengsinyot R, Leepipatpaiboon S, Gua C. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia-Oceania J Obstet Gynaecol. 1994;20:269-274.
33. Recker RR, Davies M, Hinders SM, Heaney RP, Stegman RM, Rimmel DB. Bone gain in young adolescent women. JAMA 1992;268:2403-2408.
34. Jones KP, Wild RA. Contraception for patients with psychiatric or medical disorders. Am J Obstet Gynecol. 1994;170:1575-1580.
35. Fihn SD, Latham RH, Roberts P, Running K, Stamm WE. Association between diaphragm use and urinary tract infection. JAMA. 1985;254:240-245.
36. Gleicher N, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol Surv. 1979;34:721-741.
37. Sinei SKA, Schulz KF, Lamptey PR, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol. 1990;97:412-419.
38. Ryden G, Fahraeus L, Molin L, Ahman K. Do contraceptives influence the incidence of acute pelvic inflammatory disease in women with gonorrhea? Contraception. 1979;20:149-157.
39. Seitz V, Apfel NH. Adolescent mothers and repeated childbearing: effects of a school-based intervention program. Am J Orthopsychiatry. 1993;63:572- 581.
40. Berenson AB. Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norpiant) use in adolescents 18 years of age or younger. Pediatrics. 1993;92:257-260.
41. Polaneczky M, Slap G, Forke C, Rappaport AA, Sondheimer S. The use of levonorgestrel implants (Norpiant) for contraception in adolescent mothers. N Engl J Med. 1994;331:1201-1206.
42. Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a metaanalysis. Obstet Gynecot. 1996;87:884-890.
43. Walsh TL, Bernstein GS, Grimes DA, Frezieres R, Bernstein L, Coulson AH, and the IUD Study Group. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: a pilot randomized controlled trial. Contraception. 1994;50:319-327.
44. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med. 1996;41(suppl):407-413.
45. Pariani S, Heer DM, van Arsdol MD Jr. Does choice make a difference to contraceptive use? evidence from East Java. Stud Fam Plann. 1991;22:384-390.
46. Petersen KR, Skouby SO, Sidelmann J, Mølsted-Pedersen L, Jespereen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol. 1994;171:400-405.
47. Kooiker CH, Scutchfield FD. Barriers to prescribing the copper T 380A intrauterine device by physicians. West J Med. 1990;153:279-282.
48. Mastroianni L Jr, Donaldson PJ, Kane TT, eds. Developing New Contraceptives: Obstacles and Opportunities. Washington, DC: National Academy Press; 1990:118-146.
49. Grou F, Rodrigues I. The morning-after pill - how long after? Am J Obstet Gynecol. 1994;171:1529-1534.